Danforth D N, Triche T, Doppman J L, Beazley R M, Perrino P V, Recant L
N Engl J Med. 1976 Jul 29;295(5):242-5. doi: 10.1056/NEJM197607292950502.
To determine the character of the glucagon secretion and its modification by streptozotocin, were studied the plasma of a patient with recurrent pancreatic alpha-cell carcinoma. The plasma immunoreactive glucagon level before treatment of 4.80 ng per milliliter. Biogel column separation of the plasma immunoreactive glucagon revealed four components; the predominant component had a molecular weight of 9000 daltons and was designated as proglucagon-like. This fraction constituted 60 to 90 per cent of the total circulating immunoreactive glucagon, and had a biologic activity of 32 percent of that of an immunoequivalent amount of normal (porcine) pancreatic glucagon. After treatment with streptozocin (1.5 g per square meter) the plasma immunoreactive glucagon level decreased to 0.24 ng per milliliter. Treatment was accompanied by a marked reduction in the proglucagon-like component and the appearance of pancreatic glucagon (molecular weight of 3500 daltons) as the major post-therapy fraction. These findings support the use of streptozotocin in the management of unresectable glucagon-secreting tumors.
为了确定胰高血糖素分泌的特征及其被链脲佐菌素的改变情况，对一名复发性胰腺α细胞瘤患者的血浆进行了研究。治疗前血浆免疫反应性胰高血糖素水平为每毫升4.80纳克。血浆免疫反应性胰高血糖素经生物凝胶柱分离显示有四个组分；主要组分的分子量为9000道尔顿，被命名为胰高血糖素原类似物。该组分占循环中总免疫反应性胰高血糖素的60%至90%，其生物活性为同等免疫量的正常（猪）胰腺胰高血糖素的32%。用链脲佐菌素（每平方米1.5克）治疗后，血浆免疫反应性胰高血糖素水平降至每毫升0.24纳克。治疗伴随着胰高血糖素原类似物组分的显著减少以及胰腺胰高血糖素（分子量3500道尔顿）作为治疗后主要组分的出现。这些发现支持链脲佐菌素用于不可切除的胰高血糖素分泌肿瘤的治疗。
